Brokerages Anticipate AzurRx BioPharma Inc (NASDAQ:AZRX) to Post -$0.22 Earnings Per Share

Brokerages predict that AzurRx BioPharma Inc (NASDAQ:AZRX) will report ($0.22) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for AzurRx BioPharma’s earnings. The highest EPS estimate is ($0.19) and the lowest is ($0.26). AzurRx BioPharma also posted earnings per share of ($0.22) in the same quarter last year. The business is expected to announce its next earnings report on Friday, August 9th.

On average, analysts expect that AzurRx BioPharma will report full-year earnings of ($0.77) per share for the current year, with EPS estimates ranging from ($0.85) to ($0.69). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.66) per share, with EPS estimates ranging from ($0.79) to ($0.43). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow AzurRx BioPharma.

AzurRx BioPharma (NASDAQ:AZRX) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.08).

Several analysts have weighed in on the company. HC Wainwright set a $3.00 price objective on McEwen Mining and gave the stock a “buy” rating in a report on Friday, May 24th. National Securities assumed coverage on AzurRx BioPharma in a report on Tuesday, June 11th. They set a “buy” rating and a $9.00 price objective for the company. Finally, Maxim Group reissued a “buy” rating and set a $315.00 price objective (up from $305.00) on shares of Domino’s Pizza in a report on Wednesday, April 24th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. AzurRx BioPharma presently has a consensus rating of “Buy” and an average price target of $7.58.

Several hedge funds have recently made changes to their positions in AZRX. 683 Capital Management LLC boosted its stake in shares of AzurRx BioPharma by 73.9% during the fourth quarter. 683 Capital Management LLC now owns 695,504 shares of the company’s stock valued at $842,000 after purchasing an additional 295,504 shares in the last quarter. Waldron Private Wealth LLC acquired a new stake in shares of AzurRx BioPharma during the first quarter valued at about $169,000. Finally, Regentatlantic Capital LLC acquired a new stake in shares of AzurRx BioPharma during the first quarter valued at about $48,000. 13.12% of the stock is owned by institutional investors.

NASDAQ:AZRX traded up $0.10 on Friday, hitting $1.05. 625,668 shares of the stock were exchanged, compared to its average volume of 251,481. The firm has a market capitalization of $22.11 million, a PE ratio of -1.19 and a beta of 2.23. AzurRx BioPharma has a 52 week low of $0.91 and a 52 week high of $3.75. The business has a 50-day moving average of $1.64.

AzurRx BioPharma Company Profile

AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.

Featured Article: What is the Bid-Ask Spread?

Get a free copy of the Zacks research report on AzurRx BioPharma (AZRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with's FREE daily email newsletter.